DACARBAZINE, IPILIMUMAB, IDE196 (LXS196), NIVOLUMAB, CRIZOTINIB, CRIZOTINIB, PEMBROLIZUMAB, IDE196 (LXS196)
IDE196-002
Phase 3 small_molecule active
Quick answer
DACARBAZINE, IPILIMUMAB, IDE196 (LXS196), NIVOLUMAB, CRIZOTINIB, CRIZOTINIB, PEMBROLIZUMAB, IDE196 (LXS196) for HLA-A2 negative metastatic uveal melanoma is a Phase 3 program (small_molecule) at IDEAYA Biosciences with 1 ClinicalTrials.gov record(s).
Program details
- Company
- IDEAYA Biosciences
- Indication
- HLA-A2 negative metastatic uveal melanoma
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active